Security key
10806X102
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 11,191,253
- Total 13F value
- $736,657,190
- Share change
- +1,196,498
- SEC-reported price per share
- $65.80
- Number of holders
- 146
- Value change
- +$78,440,379
- Number of buys
- 72
- Number of sells
- 56
- Shares outstanding
- 193,965,216
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2026
Institutions
146
Top holders
10
BBIO full security history
Ownership snapshot
Full 13F holder table
BridgeBio Pharma, Inc. SEC filings
BridgeBio Pharma, Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of BBIO - BridgeBio Pharma, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Janus Henderson Group Ltd.
Disclosed value leader
Jupiter Topco LLC
Comparable rows
8/15
Latest evidence
13 Aug 2026
13D/G
13F
3/4/5
Lead comparable stake: 6.8%
7 rows are not safely comparable across share classes.
13D/G row: Janus Henderson Group Ltd.
Showing 1-6 of 15 holder rows.
Quick read
Janus Henderson Group Ltd. leads the comparable SEC ownership view at 6.8%.
8 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Janus Henderson Group Ltd.'s linked filing trail.
Comparable ownership
Top 5
Janus Henderson Group Ltd.
6.8%
FARALLON CAPITAL MANAGEMENT, L.L.C.
5.5%
Farallon Capital Partners, L.P.
5.2%
BlackRock, Inc.
5.1%
VIKING GLOBAL INVESTORS LP
5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Janus Henderson Group Ltd. |
13D/G
JANUS HENDERSON GROUP PLC
|
6.8%
Reported 13D/G
· 31 Mar 2026
|
$977,092,024
13,179,013 shares
|
+$161,518,142 | 31 Mar 2026 |
| FARALLON CAPITAL MANAGEMENT, L.L.C. |
13D/G
13F
Company
|
5.5%
Reported 13D/G
· 30 Jun 2026
|
$836,992,038
10,743,063 shares
|
$0 | 30 Jun 2026 |
| Farallon Capital Partners, L.P. |
13D/G
Dapice Joshua J.
|
5.2%
Reported 13D/G
· 22 May 2026
|
$674,408,855
10,226,063 shares
|
$0 | 22 May 2026 |
| BlackRock, Inc. |
13F
13D/G
Company
|
5.1%
Reported 13D/G
· 30 Sep 2026
|
$782,601,148
12,441,196 shares
mixed-class rows
|
— | 30 Jun 2026 |
| VIKING GLOBAL INVESTORS LP |
3/4/5
13D/G
13F
10%+ Owner · Company
|
5%
Reported 13D/G
· 09 Jul 2026
|
$816,436,500
18,555,375 shares
|
— | 27 Jun 2025 |
| KKR Genetic Disorder L.P. |
13D/G
3/4/5
KKR Group Partnership L.P. · 10%+ Owner
|
4.7%
Reported 13D/G
· 13 Aug 2026
|
$719,322,695
9,232,739 shares
|
-$313,839,555 | 13 Aug 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
146
Shares
11,191,253
Rows available
146
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2026 vs Q2 2026 Across Filers
Q2 2026 holders
475
Q3 2026 holders
146
Holder diff
-329
| Investor | Q2 2026 Shares | Q3 2026 Shares | Share Diff | Share Chg % | Q2 2026 value | Q3 2026 value | Value change | Value Chg % |
|---|